Urothelial Cancer

Updated results from a large clinical trial confirm that, for some patients with bladder cancer that can be removed with surgery, receiving immunotherapy immediately afterwards is an effective treatment. Read More ›

The addition of sacituzumab govitecan (Trodelvy), an antibody–drug conjugate, to the PD-1 inhibitor pembrolizumab (Keytruda) showed encouraging antitumor activity in checkpoint inhibitor–naïve patients with metastatic urothelial cancer, according to an analysis of the results of cohort 3 from the phase 2 TROPHY-U-01 clinical trial, which were presented at the 2022 ASCO Genitourinary Cancers Symposium by Petros Grivas, MD, PhD, Clinical Director, Genitourinary Cancers Program, University of Washington School of Medicine, Seattle, and Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle. Read More ›

In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium. Read More ›

Mitomycin gel (Jelmyto), an alkylating drug, is the first and only FDA-approved treatment for patients with low-grade upper-tract urothelial cancer (UTUC), a rare cancer that affects the lining of the urinary system, and offers a nonsurgical treatment alternative for patients with this rare disease. Although the majority of urothelial cancers occur in the bladder, UTUC is part of a group of urothelial cancers that arise in the lining of the kidney or the ureter. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: